Novo Nordisk Raised Guidance. The Stock Doesn't Know It.

The market is still pricing Novo Nordisk as a company in decline. That's the story baked into a market cap down 70% from its all-time high, hammered by a February sales warning and a failed heart drug in July. But Novo quietly lifted its full-year guidance in May - and Wegovy, its core weight-loss franchise, has regained 65% of new U.S. prescriptions after losing share to Eli Lilly all of 2025. The operating setup is improving while the tape keeps falling. That's how inflection setups are born.

Here's what the numbers say the market is missing.

The old story

The narrative that sank Novo Nordisk last month is simple: U.S. pricing was crushed by a Trump administration Most-Favored-Nation deal that slashed list prices on Ozempic and Wegovy to $350 a month, from roughly $1,000 to $1,350. Patent expiries in Brazil, Canada, and China eroded the edge. Eli Lilly's tirzepatide brands overtook Wegovy and Ozempic in U.S. market share. And in late July, ziltivekimab - a late-stage inflammation drug that could have opened a cardiovascular franchise worth more than $10 billion a year - failed its Phase 3 heart trial.

Each of those facts is real. Together, they produced the selloff: the stock is down 14% over five days, 14% year-to-date, and has today plunged another 7% on heavy volume. The February sales warning - adjusted sales and profit expected to fall 5% to 13% - remains the anchor.

Except the anchor moved.

The proof point

When Novo reported Q1 2026 results on May 6, it raised its full-year 2026 guidance. Adjusted sales and operating profit are now expected to decline 4% to 12% at constant exchange rates, up from the prior forecast of 5% to 13%. The midpoint improved by one percentage point. That's not a dramatic lift, but it was a lift after the market had already been told to expect a decline.

The driver was the Wegovy pill. Launched in the U.S. in January 2026 - the first-ever oral GLP-1 for obesity - the pill accumulated 1.3 million prescriptions in the first quarter and cleared 200,000 weekly prescriptions by mid-April. Novo calls it the strongest-ever GLP-1 volume launch in the U.S. Pill sales reached 2.26 billion Danish kroner in Q1, roughly double analyst estimates. International launches are expected in the second half of 2026, pending regulatory approvals.

More importantly, Wegovy as a brand now commands 65% of all new prescriptions in the U.S. - up from the 42% share that had the market writing it off to Eli Lilly earlier in the year. CEO Mike Doustdar called it a turnaround situation on the earnings call. Broader obesity care sales rose 22% at constant exchange rates in Q1. Injectable Wegovy grew 12%. International operations grew 6%.

The Wegovy HD 7.2-milligram injectable, which produced 20.7% average weight loss in trials, was approved by the FDA in March and launched in April. It gives Novo a dose-escalation path for patients who've plateaued on the current maximum dose.

The free cash flow bridge

Free cash flow is the metric that separates a turnaround story from a turnaround hope. And this is where Novo gets complicated.

The company generated $4.9 billion in free cash flow over the trailing twelve months - down 52% year over year. That looks like a deterioration, not an inflection. But the cash-flow drop is almost entirely a capital expenditure problem, not a revenue one. Novo spent $13.9 billion on capex over the same period, building out manufacturing capacity to meet surging GLP-1 demand. Operating cash flow, by contrast, sits at $18.9 billion. Revenue growth remains at 24%. Operating margin is 45%. Return on invested capital is 40%.

The capex build-out is the ugly phase of a manufacturing ramp. It's the period where free cash flow gets eaten by the factories that will print the drug for the next decade. Once capacity catches up to demand - which Novo's management has signaled is coming - those capex outlays moderate and the cash-flow margin expands from today's 9.5% toward a much higher run rate. The 40% ROIC tells you the capital is being deployed efficiently even now.

Simple forward multiples beat complex DCF models. The stock trades at 11 times forward earnings, with a trailing PEG ratio (price-to-earnings divided by growth rate) of 0.30. A PEG below 1.0 suggests a stock is cheap relative to its growth; at 0.30, the market is pricing in a catastrophic deterioration that the Q1 results did not show.

Why the market hasn't noticed

Three reasons. First, timing: the guidance lift happened in May, three months ago, and the stock barely sustained its pop - it closed that day up just 2.3% after an intraday spike. The market's attention has been consumed by the ziltivekimab failure, which is a real disappointment but doesn't touch the core obesity franchise.

Second, the 2026 guidance is still a decline. Even at the top of the range, 4% is a cut. That's enough to keep growth investors away and value investors cautious.

Third, Q2 earnings are due tomorrow, August 5. The stock's 7% drop today looks like positioning ahead of the report. Consensus expects $11.3 billion in revenue and 82 cents per share. If Q2 prints at the top end of the raised guidance range, the narrative could shift fast.

The setup

The financial bridge is explicit: Wegovy is winning back prescription share, the oral formulation is expanding the total addressable market rather than cannibalizing injectables (Doustdar said the two are synergistic), international launches are coming, and capacity build-out will eventually unlock a dramatically higher free-cash-flow margin. Revenue is still growing at roughly 24%. Operating margin is 45%. The stock trades at 11 times forward earnings.

If the 2026 decline proves to be at the top end of the new range - a 4% contraction rather than 12% - and the Wegovy pill trajectory holds or accelerates through the second half, the market's view of the next 12-18 months changes quickly. A rerating to even a modest multiple on improving profitability would be material.

The target isn't a precise number - it's a direction. A stock trading at 11 times forward earnings with 24% revenue growth, a 45% operating margin, and a GLP-1 franchise that just regained two-thirds of new prescriptions has upside if the operational momentum sustains. The question is whether you believe the Q1 trajectory is durable or a one-quarter blip.

The tripwire

Discipline over ego. The setup has clear invalidation points.

If Q2 earnings - coming tomorrow - come in near the bottom of the guidance range (a 12% decline), or if Wegovy's prescription share slips back below 60%, the turnaround narrative loses steam. A second quarter of worsening U.S. pricing, beyond what's already guided, would confirm the old story is right.

If the Wegovy pill fails to launch internationally in the second half of 2026, or if Eli Lilly's competing oral drug Foundayo (launched April 2026) pulls share faster than expected, the expansion thesis weakens.

And if capex keeps consuming cash without a visible inflection in free-cash-flow margin by mid-2027, the manufacturing ramp story becomes a cash trap rather than a bridge to profitability.

The selloff matters less than the fact that expectations have already reset while the numbers have not broken. The market is still pricing the February warning while the Q1 operating results told a different story. Whether that difference persists through Q2 is the hinge point.

The ziltivekimab failure erased $30 billion from market value. It's a strategic miss. But it doesn't change the fact that Novo's core business is growing at 24%, winning back share, and trading at a multiple that would be considered generous if applied to a company actually declining. That gap between the tape and the operating path is the setup. The tripwire is what Q2 says about whether the gap narrows or widens.